WO1993017684A3 - Enantiomeric hydroxylated xanthine compounds - Google Patents

Enantiomeric hydroxylated xanthine compounds Download PDF

Info

Publication number
WO1993017684A3
WO1993017684A3 PCT/US1993/002304 US9302304W WO9317684A3 WO 1993017684 A3 WO1993017684 A3 WO 1993017684A3 US 9302304 W US9302304 W US 9302304W WO 9317684 A3 WO9317684 A3 WO 9317684A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
enantiomeric
xanthine compounds
hydroxylated
hydroxylated xanthine
Prior art date
Application number
PCT/US1993/002304
Other languages
French (fr)
Other versions
WO1993017684A2 (en
Inventor
James A Bianco
Paul Woodson
David Porubek
Jack Singer
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Priority to JP5516036A priority Critical patent/JP2753395B2/en
Priority to AT93908327T priority patent/ATE230990T1/en
Priority to DE69332634T priority patent/DE69332634T2/en
Priority to DK93908327T priority patent/DK0584347T3/en
Priority to EP93908327A priority patent/EP0584347B1/en
Priority to CA002112239A priority patent/CA2112239C/en
Priority to KR1019940703122A priority patent/KR950700066A/en
Priority to AU39190/93A priority patent/AU669702B2/en
Publication of WO1993017684A2 publication Critical patent/WO1993017684A2/en
Publication of WO1993017684A3 publication Critical patent/WO1993017684A3/en
Priority to NO943263A priority patent/NO943263L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)

Abstract

There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an omega -1 alcohol of a straight chain alkyl (C5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
PCT/US1993/002304 1992-03-04 1993-03-01 Enantiomeric hydroxylated xanthine compounds WO1993017684A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP5516036A JP2753395B2 (en) 1992-03-04 1993-03-01 Enantiomeric hydroxylated xanthine compounds
AT93908327T ATE230990T1 (en) 1992-03-04 1993-03-01 ENANTIOMERIC HYDROXYLATED XANTHINE COMPOUNDS
DE69332634T DE69332634T2 (en) 1992-03-04 1993-03-01 ENANTIOMIC HYDROXYLATED XANTHINE COMPOUNDS
DK93908327T DK0584347T3 (en) 1992-03-04 1993-03-01 Enantiomeric hydroxylated xanthine compounds
EP93908327A EP0584347B1 (en) 1992-03-04 1993-03-01 Enantiomeric hydroxylated xanthine compounds
CA002112239A CA2112239C (en) 1992-03-04 1993-03-01 Enantiomeric hydroxylated xanthine compounds
KR1019940703122A KR950700066A (en) 1992-03-04 1993-03-01 Enantiomeric hydroxylated xanthine compounds
AU39190/93A AU669702B2 (en) 1992-03-04 1993-03-01 Enantiomeric hydroxylated xanthine compounds
NO943263A NO943263L (en) 1992-03-04 1994-09-02 Enantiomeric hydroxylated xanthine compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US84635492A 1992-03-04 1992-03-04
US07/846,354 1992-03-04
US92666592A 1992-08-07 1992-08-07
US07/926,665 1992-08-07

Publications (2)

Publication Number Publication Date
WO1993017684A2 WO1993017684A2 (en) 1993-09-16
WO1993017684A3 true WO1993017684A3 (en) 1993-11-25

Family

ID=27126630

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/002304 WO1993017684A2 (en) 1992-03-04 1993-03-01 Enantiomeric hydroxylated xanthine compounds

Country Status (17)

Country Link
US (8) US5652243A (en)
EP (1) EP0584347B1 (en)
JP (4) JP2753395B2 (en)
KR (1) KR950700066A (en)
CN (1) CN1040646C (en)
AT (1) ATE230990T1 (en)
AU (1) AU669702B2 (en)
CA (1) CA2112239C (en)
CZ (1) CZ212394A3 (en)
DE (1) DE69332634T2 (en)
DK (1) DK0584347T3 (en)
ES (1) ES2191013T3 (en)
IL (1) IL104943A (en)
NO (1) NO943263L (en)
NZ (1) NZ247038A (en)
PT (1) PT584347E (en)
WO (1) WO1993017684A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693105B1 (en) * 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US5795897A (en) * 1992-11-18 1998-08-18 Cell Therapeutics, Inc. Oxohexyl methylxanthine compounds
WO1995013075A1 (en) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
WO1995019171A1 (en) * 1994-01-14 1995-07-20 Cell Therapeutics, Inc. Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
US5807861A (en) * 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
EP0759915B1 (en) * 1994-05-16 2002-10-16 Cell Therapeutics, Inc. Asymmetric synthesis of chiral secondary alcohols
US5643893A (en) * 1994-06-22 1997-07-01 Macronex, Inc. N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
DE4430128A1 (en) * 1994-08-25 1996-02-29 Hoechst Ag Combination preparation with immunosuppressive, cardiovascular and cerebral effects
DE4430127A1 (en) * 1994-08-25 1996-03-14 Hoechst Ag Combination preparation containing cyclosporin A or FK506 and a xanthine derivative
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US6136964A (en) * 1996-03-19 2000-10-24 Cell Therapeutics, Inc. Mammalian lysophosphatidic acid acyltransferase
CA2291516A1 (en) * 1997-05-27 1998-12-03 Cell Therapeutics, Inc. Mammalian lysophosphatidic acid acyltransferase
AU9449398A (en) * 1997-10-10 1999-05-03 Imperial College Innovations Ltd. Use of csaidtm compounds for the management of uterine contractions
US6111329A (en) * 1999-03-29 2000-08-29 Graham; Gregory S. Armature for an electromotive device
WO2001022950A2 (en) 1999-09-24 2001-04-05 Shire Biochem Inc. Diosolane nucleoside analogs for the treatment or prevention of viral infection
FR2804867B1 (en) * 2000-02-15 2002-09-20 Hoechst Marion Roussel Inc APPLICATION OF XANTHINE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION OR TREATMENT OF OSTEOPOROSIS
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
CA2424029C (en) 2000-09-29 2008-01-29 Cordis Corporation Coated medical devices
PL222211B1 (en) 2001-06-26 2016-07-29 Amgen Fremont Inc Antibodies to opgl
WO2003002187A2 (en) * 2001-06-26 2003-01-09 Photomed Technologies, Inc. Multiple wavelength illuminator
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
NZ593428A (en) 2002-09-06 2013-01-25 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
KR101100601B1 (en) 2004-02-14 2011-12-29 글락소스미스클라인 엘엘씨 Novel compounds
EP1841448A2 (en) * 2004-12-30 2007-10-10 Diakine Therapeutics, Inc. Pharmaceutical compositions and methods for restoring beta-cell mass and function
JP2009504592A (en) 2005-08-10 2009-02-05 スミスクライン・ビーチャム・コーポレイション Xanthine derivatives as selective HM74A agonists
US20080059313A1 (en) * 2006-08-30 2008-03-06 Oblong John E Hair care compositions, methods, and articles of commerce that can increase the appearance of thicker and fuller hair
WO2009107072A1 (en) * 2008-02-29 2009-09-03 The Procter & Gamble Company Hair care compositions and methods for increasing hair diameter
US9133062B2 (en) 2012-11-21 2015-09-15 Corning Incorporated Method of firing cordierite bodies
EP2996775A1 (en) 2013-05-16 2016-03-23 The Procter & Gamble Company Hair thickening compositions and methods of use
CN103880861B (en) * 2014-02-21 2016-02-03 温州医科大学 A kind of 4,6-dimethyl-oxazoles also [5,4-d] pyrimidine-5 acting on FGF receptor, 7(4H, 6H)-derovatives
CN111233863B (en) * 2014-10-09 2022-10-25 广东众生睿创生物科技有限公司 Hydroxyl purine compound and application thereof
BR112017007194B1 (en) * 2014-10-09 2023-11-07 Guangdong Raynovent Biotech Co., Ltd HYDROXYL PURINE COMPOUNDS AND USE THEREOF
ES2784826T3 (en) * 2015-10-29 2020-10-01 Guangdong Raynovent Biotech Co Ltd Crystalline form of a 4H-pyrazole [1,5-] benzimidazole compound, method of preparation thereof and intermediate thereof
WO2020035482A1 (en) 2018-08-13 2020-02-20 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515795A (en) * 1968-11-25 1985-05-07 Hoechst Aktiengesellschaft Pharmaceutical compositions
US4576947A (en) * 1967-12-16 1986-03-18 Hoechst Aktiengesellschaft Pharmaceutical compositions
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
US4833146A (en) * 1985-07-19 1989-05-23 Hoechst Aktiengesellschaft Tertiary hydroxyalkylxanthines, medicaments containing them and their use
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5039666A (en) * 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422107A (en) * 1964-09-05 1969-01-14 Albert Ag Chem Werke Certain oxoalkyldimethylxanthines and a process for the preparation thereof
US3373433A (en) * 1964-12-16 1968-03-12 Sylvania Electric Prod Dual linear/circular polarization spiral antenna
US4525309A (en) * 1983-03-15 1985-06-25 Washington State University Research Foundation, Inc. Lewis acid catalysis of the homologation of boronic esters with haloalkylmetal reagents
US5272153A (en) * 1986-12-31 1993-12-21 Hoechst-Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5096906A (en) * 1986-12-31 1992-03-17 University Of Virginia Alumni Patents Foundation Method of inhibiting the activity of leukocyte derived cytokines
DE3817955A1 (en) * 1988-05-27 1989-11-30 Hoechst Ag MEDICINAL PRODUCT CONTAINING TNF INHIBITOR
DE3942871A1 (en) * 1989-12-23 1991-06-27 Hoechst Ag R - (-) - 1- (5-HYDROXYHEXYL) -3-METHYL-7-PROPYLXANTHINE, METHOD OF ITS PREPARATION AND MEDICAMENTS CONTAINING THIS COMPOUND
DE3942872A1 (en) * 1989-12-23 1991-06-27 Hoechst Ag METHOD FOR THE ENANTIOSELECTIVE PRESENTATION OF ((OMEGA) -1) -HYDROXYALKYLXANTHINES
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions
JP3566719B2 (en) * 1991-05-24 2004-09-15 フレッド ハッチンソン キャンサー リサーチ センター Modulation of cellular response to exogenous stimuli
MX9203323A (en) * 1991-07-11 1994-07-29 Hoechst Ag THE USE OF XANTHINE DERIVATIVES FOR THE TREATMENT OF SECONDARY INJURIES OF THE NERVOUS CELLS AND FUNCTIONAL DISORDERS AFTER CRANIAL-BRAIN TRAUMA.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4576947A (en) * 1967-12-16 1986-03-18 Hoechst Aktiengesellschaft Pharmaceutical compositions
US4515795A (en) * 1968-11-25 1985-05-07 Hoechst Aktiengesellschaft Pharmaceutical compositions
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
US4833146A (en) * 1985-07-19 1989-05-23 Hoechst Aktiengesellschaft Tertiary hydroxyalkylxanthines, medicaments containing them and their use
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
US5039666A (en) * 1990-10-30 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. Aminoglycoside composition having substantially reduced nephrotoxicity induced by the aminoglycoside

Also Published As

Publication number Publication date
DK0584347T3 (en) 2003-02-24
US5621102A (en) 1997-04-15
NO943263L (en) 1994-11-02
DE69332634D1 (en) 2003-02-20
IL104943A (en) 1998-12-27
NO943263D0 (en) 1994-09-02
CN1085557A (en) 1994-04-20
US5739138A (en) 1998-04-14
AU3919093A (en) 1993-10-05
EP0584347A4 (en) 1995-04-26
CN1040646C (en) 1998-11-11
JPH08259565A (en) 1996-10-08
IL104943A0 (en) 1993-07-08
WO1993017684A2 (en) 1993-09-16
US5620984A (en) 1997-04-15
US5612349A (en) 1997-03-18
JP2753395B2 (en) 1998-05-20
NZ247038A (en) 1995-02-24
US5965564A (en) 1999-10-12
CA2112239A1 (en) 1993-09-16
ATE230990T1 (en) 2003-02-15
EP0584347A1 (en) 1994-03-02
CA2112239C (en) 2000-05-09
DE69332634T2 (en) 2003-05-08
PT584347E (en) 2003-06-30
AU669702B2 (en) 1996-06-20
US5652243A (en) 1997-07-29
EP0584347B1 (en) 2003-01-15
US5629315A (en) 1997-05-13
KR950700066A (en) 1995-01-16
US5792772A (en) 1998-08-11
ES2191013T3 (en) 2003-09-01
JP2004002467A (en) 2004-01-08
CZ212394A3 (en) 1995-09-13
JP2002087961A (en) 2002-03-27
JPH06509584A (en) 1994-10-27

Similar Documents

Publication Publication Date Title
CA2112239A1 (en) Enantiomeric Hydroxylated Xanthine Compounds
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
NZ236589A (en) A-nor-steroid-3-carboxylic acid derivatives and pharmaceutical compositions
AU589378B2 (en) Pharmaceutical compositions containing inositol triphosphates
MY115339A (en) Compositions containing micronized nebivolol
ES378823A1 (en) Aminobenzocycloalkane compounds
IL74497A (en) Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
TW225534B (en)
AU2524692A (en) Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
IL114599A0 (en) Substituted pyrimidine compounds their preparation and pharmaceutical compositions containing them
MY105328A (en) Blocking agents of edrf effect or formation for the treatment of shock.
MY117090A (en) Substituted benzamidines, their preparation and their use as pharmaceutical compounds
GR850472B (en)
ES2004985A6 (en) 1-(4-Aminophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5H-2,3-benzodiazepine and acid addition salts thereof same
EP1026157A3 (en) Method for the synthesis of huperzine A and analogs thereof and compounds useful therein
CA2027351A1 (en) Emulsion of lipid containing a prostaglandin analogue
AU6319480A (en) 2-hydroxyalkyl-3,4,5-trihydroxypiperidines
EP0194093A3 (en) Substituted heterocyclic acrylic acids and esters, their preparation and pharmaceutical compositions containing them
MD502G2 (en) New adenozine derivatives, methods of obtainitg thereof, farmaceutical compositions on the base thereof
ATE66673T1 (en) 2-PYRROLIDONE DERIVATIVES, METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITIONS AND APPLICATION.
EP0186023A3 (en) Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
MX9204815A (en) HEXAHIDROBENZO [F] QUINOLINONAS AND PHARMACEUTICAL FORMULATION THAT INCLUDES THEM.
AU2291483A (en) Carbamyloxybenzhyrol derivatives
HUT70761A (en) Alkyl derivatives of trazodone having action for central nervous system, pharmaceutical compositions for preparing thereof
MX9303392A (en) DERIVATIVES OF IMIDAZO BENZOXAZIN-1-ONA SUBSTITUTED AND PROCESS FOR ITS PREPARATION.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA FI HU JP KR NO RU UA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/22-11/22,13/22-16/22 AND 19/22-22/22,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;AFTER THE RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE UNITED STATES PATENT AND TRADEMARK OFFICE IN ITS CAPACITY AS INTERNATIONAL SEARCHING AUTHORITY

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA FI HU JP KR NO RU UA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1993908327

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2112239

Country of ref document: CA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 1993908327

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993908327

Country of ref document: EP